A lineage-specific STAT5B^N642H mouse model to study NK-cell leukemia

Natural killer (NK)-cell malignancies are rare types of cancer that originate from the abnormal growth and proliferation of NK cells. They can be aggressive and challenging to treat. The World Health Organization distinguishes the following types of NK-cell neoplasms: extranodal NK/T-cell lymphoma (ENKL), aggressive NK-cell leukemia (ANKL), chronic active Epstein-Barr virus (EBV) infection of NK cells, and NK-large granular lymphocytic leukemia (NK-LGLL), formerly called chronic lymphoproliferative disorder of NK cells.¹ ENKL and ANKL are EBV-positive and associated with a poor prognosis.¹ NK-LGLL is usually EBV-negative, represents a subset of LGLL, and is largely an indolent disease that may develop into an aggressive NK-cell malignancy.^1-6 The factors that trigger the transformation of an indolent into an aggressive form of NK-cell leukemia are unknown.

Signal transducer and activator of transcription 5 (STAT5) is a crucial component of the Janus kinase (JAK)/STAT pathway essential for the survival, proliferation, and functionality of various hematopoietic cell types.⁷ In leukemia, STAT activity is often enhanced by aberrant upstream tyrosine kinase activation, copy number gains,⁸ or activating mutations within STAT3/5B proteins themselves.^9-14 STAT5 is the most frequently deregulated member of the JAK/STAT family in hematopoietic cancer.^15-17 It comprises 2 individual genes, STAT5A and STAT5B, which express proteins with high homology.^7,18-20 Although STAT5A and STAT5B have largely redundant functions, they both have some individual roles.^18,21 STAT5B is the dominant gene product in T and NK cells and promotes their survival, proliferation, and cytotoxicity. Stat5b-deficient mice show reduced NK-cell numbers, and humans with STAT5B deficiency experience immunodeficiencies caused by impairment in T-, regulatory T-, and NK-cell differentiation and activation.^18,22-32 

Activating STAT5 mutations in hematological cancer predominantly occur in STAT5B.¹⁸ The most frequent STAT5B gain-of-function (GOF) mutation, STAT5B^N642H, has been described in various forms of lymphoproliferative disorders, including T-cell lymphoma/leukemia, γδ–T-cell lymphoma, LGLL, and NK-cell malignancies.^{9,11,13,14,33-43} Activating STAT5B mutations have been detected in various NK-cell malignancies including cases of NK-LGLL and are linked to an aggressive clinical course.^{5,6,11,14,40,41,43-46} STAT5B^N642H gives a proliferative advantage to human NK cells,⁴³ but whether it alone is sufficient to drive NK-cell leukemia remains unknown.

Compared with the wild-type allele, STAT5B^N642H enhances dimer stability and causes elevated and prolonged STAT5B tyrosine phosphorylation. As a consequence, STAT5B target gene expression is increased.^{9-11,34,39,42} But even in the presence of activating STAT5B mutations, upstream cytokine signaling is necessary to activate JAK/STAT5 signaling.^10,43,47 In immune cells, STAT5 signaling is induced by various cytokines, including interleukin-2 (IL-2), IL-7, and IL-15, which promote cell proliferation, survival, and maturation.^48,49 IL-15 overexpression has been implicated in leukemogenesis because IL-15 transgenic mice develop NK- or NK T-cell (NKT-cell) leukemia.^50-52 Another transgenic mouse model expressing human IL-15 and a transgenic mouse model expressing human STAT5B^N642H in the hematopoietic system under the vav promoter (vav-N642H) develop a lethal CD8⁺ T-cell expansion.^10,53 The rapid development of the highly aggressive CD8⁺ T-cell disease may mask and prevent the development of other malignancies because transplantation of NKT or γδ T cells from vav-N642H mice lead to leukemia development.^9,54 To investigate the oncogenic potential of STAT5B^N642H in other cell types, we generated a lox-stop-lox STAT5B^N642H transgenic mouse model that enables lineage-restricted transgene expression driven by cell type-specific expression of the Cre recombinase. The use of Cre recombinase under an NKp46⁺ cell–specific promoter allows for us to study the role of STAT5B^N642H in NK cells (N642H^NK/NK mice). Here, the transcriptional changes associated with STAT5B^N642H expression in leukemic NK cells closely resemble disease signatures of human NK-cell leukemia with STAT5B GOF mutations, enabling the assessment of further treatment options using the novel NK-cell leukemia model.

Rosa26 (R26)–targeted lox-stop-lox STAT5B and STAT5B^N642H knockin mice were generated using a STOP-EGFP-ROSA-CAG targeting vector⁵⁵ (obtained from Thomas Wunderlich, University of Cologne). This vector integrates into the R26 locus enabling transgene expression under the CAG promoter coupled to internal ribosome entry site (IRES)-controlled enhanced green fluorescent protein (eGFP) expression upon Cre recombinase–mediated excision of the floxed STOP cassette. C-terminally V5-tagged human STAT5B or STAT5B^N642H transgenes were cloned downstream of the STOP cassette into the STOP-EGFP-ROSA-CAG targeting vector. A control construct lacking a transgene but containing IRES-controlled eGFP downstream of the STOP cassette was included. The 3 R26-LSL knockin lines B6-Gt(ROSA)26Sor^{tm1(STAT5B-N642H)}Biat, B6-Gt(ROSA)26Sor^tm2(STAT5B)Biat, and B6-Gt(ROSA)26Sor^tm3(EGFP)Biat were generated using the linearized vectors for electroporation into C57BL/6N embryonic stem (ES) cells (parental ES cell line C2; stock number: 011989-MU; Citation ID: RRID: MMRRC_011989-MU). Positively screened ES cell clones were injected into BALB/c blastocysts, transferred to pseudopregnant mice, and chimeric offspring were bred with C57BL/6N mice. Germ line transmission was confirmed by polymerase chain reaction (forward primers: 5'-GCACTTGCTCTCCCAAAGTCGCTC-3' [R26_wt_fw] and 5'-CGCCGACCACTACCAGCAGAACAC-3' [R26_EGFP_fw]; reverse primer: 5'-ACAACGCCCACACACCAGGTTAGC-3' [R26_wt_rev]) and selected for further crossing to Cre lines.

Frozen liver samples from aged nondiseased and diseased mice (healthy Cre negative [neg; n = 3], GFP^NK/NK [n = 2], STAT5B^NK/NK [n = 3], and N642H^NK/NK [n = 5]; diseased N642H^NK/NK [n = 8]) were thawed, and (GFP⁺) CD3^–NK1.1⁺ NK cells (and additionally CD3⁺NK1.1⁺ cells from number 8) were sorted into a SMARTSeq lysis buffer using a CytoFlex SRT Sorter (Beckman Coulter). Libraries were constructed using the SMART-SEQ3 method⁵⁶ at the Vienna BioCenter Core facilities, member of the Vienna BioCenter, Vienna, Austria. Sequencing was performed on an Illumina NovaSeq 6000 system (50-bp paired-end; Illumina, San Diego, CA). Sequencing reads were quality controlled using the FastQC software (version 0.12.1).⁵⁷ Detailed RNA sequencing (RNA-Seq) analysis was performed as described in the supplemental Methods, available on the Blood website. The RNA-Seq data reported in this article have been deposited in the ArrayExpress database (accession ID: E-MTAB-13797).

Primary samples were obtained from bone marrow (BM) or peripheral blood of patients diagnosed with NK-cell neoplasms (n = 64) or healthy donors (peripheral blood mononuclear cells) after informed consent. Three patients harbored activating STAT5B mutations previously described⁴⁴ (1 with STAT5B^N642Hmutation, a second with STAT5B^Q706L mutation, and the third with both STAT5B^Y665F and STAT5B^V712E mutations). DNA and RNA were isolated from total leukocytes, followed by whole-genome sequencing and RNA-Seq at the Munich Leukemia Laboratory as previously described.⁵⁸ Reads were aligned to human reference genome (GRCh37, Ensembl annotation) using Isaac aligner (v3.16.02.19). Tumor-unmatched normal variant calling was performed with a pool of sex-matched DNA (Promega, Madison, WI) using Strelka (v.2.4.7). Variants were queried against the gnomAD database (v.2.1.1) to remove common germ line calls and annotated with Ensembl VEP. Analysis was restricted to protein-altering and canonical splice-site variants. For transcriptome analysis, the TruSeq Total Stranded RNA kit was used, starting with 250 ng of total RNA, to generate RNA libraries following the manufacturer’s recommendations (Illumina). A total of 2× 100-bp paired-end reads were sequenced on the NovaSeq 6000 (Illumina), with a median of 50 million reads per sample. Reads were mapped with STAR aligner (v2.5.0a) to the human reference genome hg19 (RefSeq annotation). Gene- and transcript-specific read abundance was calculated with Cufflinks (v2.2.1). For gene expression analysis, estimated read counts for each gene were normalized by trimmed mean of M-values normalization, and the resulting log2 counts per million were used.

The appropriate statistical method was used based on testing for normal distribution and homogeneity of variance. Tests were performed using GraphPad Prism. The statistical test is indicated in the corresponding figure legends.

Animal experiments were discussed and approved by the ethics and animal welfare committee of the University of Veterinary Medicine Vienna and the national authority (Austrian Federal Ministry of Education, Science and Research) in accordance with good scientific practice guidelines and national legislation, under licenses BMBWF-68.205/0103-WF/V/3b/2015, BMBWF-68.205/0010-V/3b/2019, BMBWF-68.205/0174-V/3b/20182022-0.762.012, and 2023-0.108.862, 2022-0.404.452.

We generated mice with a human V5-tagged STAT5B^N642H transgene and IRES-eGFP under the CAG promoter downstream of a lox-stop-lox-cassette integrated into the Rosa26 locus. The animals were crossed to Vav-Cre mice⁵⁹ (N642H^vav/+) to study the effects of STAT5B^N642H on the hematopoietic system (Figure 1A). We validated the presence of the STAT5B^N642H transgene by analyzing the expression of eGFP and the V5 tag in N642H^vav/+ mice (Figure 1B; supplemental Figure 1A-B). N642H^vav/+ BM cells displayed increased levels of tyrosine-phosphorylated STAT5 (pYSTAT5) compared with control BM cells, although reduced levels when compared with the pYSTAT5 levels of vav-N642H mice¹⁰ (Figure 1B). 8-week-old N642H^vav/+ mice had an elevated BM cellularity and an enlarged hematopoietic stem cell pool under homeostatic conditions (supplemental Figure 1C-F). Numbers of erythroid cells (Ter119⁺) and NK cells (CD3^–NK1.1⁺) were reduced, whereas T cells (CD3⁺CD4⁺ or CD3⁺CD8⁺), B cells (CD19⁺), and myeloid cells (CD11b⁺Gr1⁺) were increased in the BM (supplemental Figure 1G). At age 8 weeks, N642H^vav/+ mice showed splenomegaly (Figure 1C) with significantly expanded myeloid and B-cell compartments (Figure 1D). The peripheral blood of N642H^vav/+ mice lacked any significant alterations in the composition of leukocytes, except for a decrease in the frequency of CD4⁺ T cells (supplemental Figure 1H).

Upon aging, all N642H^vav/+ mice developed a hematopoietic malignancy with a median survival of 186 days (Figure 1E). The mice suffered from reduced body weight and enlarged spleen and lymph nodes (Figure 1F-G; supplemental Figure 1I-J). They had significantly elevated numbers of mature hematopoietic cell types in spleen, blood, and lymph nodes but not in the BM (Figure 1G; supplemental Figure 1K-M). Cell numbers were elevated in all lineages, and no cell type was dominantly expanded (Figure 1G; supplemental Figure 1K-M). Blood smears of the diseased N642H^vav/+ mice showed leukemic blast-like cells (Figure 1H). The immune cell infiltration in the lungs was associated with a disruption of the regular lung architecture (Figure 1I).

To test whether the hematopoietic malignancy is transplantable, we injected Ly5.2⁺ splenic cells of diseased N642H^vav/+ and healthy aged control mice into immunodeficient NOD scid gamma (NSG) recipients (NOD.Cg-Prkdcˢᶜⁱᵈ Il2rgᵗᵐ¹ᵂʲˡ/SzJ). All recipients of N642H^vav/+ splenocytes developed a disease within 3 months (Figure 2A). Ly5.2⁺ N642H^vav/+ cells densely infiltrated the BM, spleen, and lungs of the recipients, indicating development of leukemia (Figure 2B; supplemental Figure 2A-C). The infiltrating cell types were either T or NKT cells (Figure 2C-D). N642H^vav/+ T and NKT cells expressed almost exclusively T-cell receptor β (TCRβ) but not TCRγδ (Figure 2E-F). CD4⁺ and CD8⁺ T/NKT cells expanded in the recipient mice (Figure 2E,G). This argues against the idea that a specific T/NKT-cell subtype is driving leukemia. The diseases that develop in N642H^vav/+ mice closely resemble the T- /NKT-cell diseases observed in patients harboring the STAT5B^N642H mutation.⁹ 

Despite the presence of an activating STAT5B mutation, N642H^vav/+ mice did not develop NK-cell leukemia. To investigate the oncogenic potential of STAT5B^N642H in NK cells, we ectopically expressed human STAT5B or STATB^N642H in 2 human NK-cell lines (IMC-1 and KHYG-1) that harbor TP53 mutations but lack mutations in the JAK/STAT3/5 pathway.^40,60 Transduction with STAT5B or STAT5B^N642H decreased cell growth in standard IL-2 culture (100 U/mL) but gave a growth advantage at limited IL-2 concentrations (25 U/mL; supplemental Figure 3A-F). In the absence of IL-2, STAT5B^N642H was required for cytokine-independent growth (Figure 3A-B; supplemental Figure 3C,F). This prompted us to test whether STAT5B^N642H enhances the disease-initiating potential of KHYG-1 and IMC-1 cells in vivo (Figure 3C). When injected into NSG mice, STAT5B^N642H-expressing IMC-1 cells accelerated disease onset significantly compared with parental and nonmutant STAT5B-expressing cells (Figure 3D). In contrast, neither the parental nor the STAT5B-overexpressing KHYG-1 cells caused disease in NSG recipient mice. All STAT5B^N642H-transduced KHYG1 cells induced leukemia within 21 to 25 days (Figure 3D). The disease primarily manifested in the BM and the liver (Figure 3E-G; supplemental Figure 3G), both typical sites of disease manifestation in patients with NK-cell leukemia.^11,14,61,62 

To investigate the oncogenic role of STAT5B^N642H in NK cells in detail, we crossed the B6-Gt(ROSA)26Sor^{tm1(STAT5B-N642H)} mice to Ncr1-iCreTg mice⁶³ (N642H^NK/NK). These mice express STAT5B^N642H exclusively in NKp46⁺ cells, which mainly represent mature NK cells.^64,65 A human STAT5B transgene-expressing mouse strain (STAT5B^NK/NK) and a strain solely expressing eGFP (GFP^NK/NK) were used as controls (Figure 4A). All Cre-positive litters expressed GFP in NK cells (supplemental Figure 4A). We confirmed the V5-tagged transgene expression and elevated STAT5 protein levels in STAT5B^NK/NK and N642H^NK/NK NK cells compared with GFP^NK/NK NK cells (Figure 4B).

STAT5B^N642H molecules have an enhanced capacity for self-dimerization and a reduced susceptibility to inactivation by dephosphorylation.⁹ Compared with STAT5B^NK/NK NK cells, N642H^NK/NK splenic NK cells displayed enhanced pYSTAT5 levels ex vivo already in an unstimulated state and more pronounced after IL-15 stimulation (supplemental Figure 4C-D). Elevated pYSTAT5 levels were also observed in vitro in IL-2–cultured N642H^NK/NK splenic NK cells (Figure 4B; supplemental Figure 4B). Upon cytokine withdrawal, pYSTAT5 dephosphorylation was delayed in N642H^NK/NK compared with control NK cells (Figure 4B; supplemental Figure 4B-D).

Adult N642H^NK/NK mice show increased NK-cell numbers in blood, spleen, and BM (Figure 4C-E; supplemental Figure 4E-G). Notably, an expansion of NK cells was already detectable in the blood of N642H^NK/NK mice as early as age 4 weeks (supplemental Figure 4H). Furthermore, N642H^NK/NK mice display more mature NK cells in the BM and spleen than control strains (Figure 4F-G; supplemental Figure 4I). Furthermore, STAT5B^N642H expression in NK cells was associated with increased survival and reduced apoptosis ex vivo (Figure 4H). The data are consistent with the idea that STAT5B promotes NK-cell survival and maturation.³² We found enhanced levels of granzyme B and perforin in N642H^NK/NK NK cells (supplemental Figure 4J), supporting the role of STAT5B in regulating the levels of cytolytic molecules.^22,23,30,32 

The oncogenic potential of STAT5B^N642H in NK cells was assessed by aging of the animals. Although the majority of N642H^NK/NK mice maintained an indolent expansion of NK cells, 8 of 24 (∼33%) developed disease symptoms within 17 months. One STAT5B^NK/NK and 1 Cre neg control mouse (of 50 control mice) were euthanized due to unspecific age-related symptoms without any signs of leukemia after 486 and 518 days, respectively (Figure 5A). The diseased N642H^NK/NK mice consistently displayed a leukemic phenotype and suffered from significant body weight loss, splenomegaly, and an expansion of GFP⁺ cells in various organs, including spleen, liver, BM, and blood (Figure 5B-C; supplemental Figure 5A-B; supplemental Table 1). NK cells were the predominantly expanded cell type in the spleen of 5 of 8 diseased N642H^NK/NK mice (numbers 1-5). One of the diseased mice (number 8) displayed an expansion of CD3⁺NK1.1⁺ γδ T cells, whereas 2 other mice (numbers 6 and 7) had a predominant expansion of GFP⁺ cells lacking both NK- and T-cell markers (CD3^– TCR^–NK1.1^– NKp46^– cells) (Figure 5D-E; supplemental Figure 5C; supplemental Table 1). Flow cytometric analysis revealed a downregulation of CD11b, CD49b, and NKp46 and a partial increase in CD27, CD49a, and NKG2D expression in diseased N642H^NK/NK NK cells. KLRG1 expression was significantly increased in diseased N642H^NK/NK NK cells (Figure 5F-G; supplemental Figure 5D-F). Similar deregulations were partially observed in NK cells from nondiseased N642H^NK/NK mice, which however more closely resembled control NK cells (Figure 5B,F-G; supplemental Figure 5D; supplemental Table 1).

To confirm the expansion of leukemic cells as the disease cause, we transplanted splenic cells from the diseased N642H^NK/NK mice (numbers 1-4 and 6-8) into NSG mice (Figure 6A). Transplantation initiated a fast-progressing leukemia in all recipient mice. The diseased mice suffered from weight loss, hepatosplenomegaly, anemia, and multiple organ infiltration. A leukemia with NK-cell phenotype was observed in ∼70% of the mice who received transplantation (Figure 6B-E; supplemental Figure 6A-H; supplemental Table 2). The transplantation of splenocytes from the mouse that had a lethal expansion of CD3⁺NK1.1⁺ TCRγδ⁺ T cells (number 8) verified a disease driven by STAT5B^N642H-expressing γδ T cells. The transplantation of splenic cells with an accumulation of GFP⁺ CD3^– TCR^–NK1.1^– NKp46^– cells (numbers 6 and 7) revealed that the mice suffered more likely from an NK-cell leukemia than an acute leukemia of T-cell origin because there was a pronounced NK1.1⁺ but not a CD3⁺ or TCR⁺ population upon transplantation (supplemental Figure 6A-H). We observed leukemic blast-like cells in the blood of all diseased recipient mice (Figure 6F). To gauge the potential for immune evasion of the transformed N642H^NK/NK NK cells, we performed parallel transplantations into NSG and Ly5.1 mice (Figure 6G). The N642H^NK/NK leukemic cells incited disease in both NSG and Ly5.1 mice within a similar time frame and showed comparable organ infiltration (Figure 6H; supplemental Figure 6I-M). Furthermore, we established stable NK-cell lines from diseased N642H^NK/NK mice and tested their cytokine dependency. All tested cell lines exhibited a dependency on IL-2. One cell line (number 3) displayed a growth advantage under reduced IL-2 levels (supplemental Figure 6N-O). In summary, N642H^NK/NK mice predominantly develop a transplantable NK-cell leukemia, which evades immune recognition.

To investigate the transcriptional changes in STAT5B^N642H-driven NK-cell leukemia, we performed RNA-Seq of ex vivo sorted NK cells from the livers of diseased N642H^NK/NK and aged nondiseased control (Cre neg and GFP^NK/NK), STAT5B^NK/NK and N642H^NK/NK mice, and γδ T cells of the diseased N642H^NK/NK mouse 8. Diseased N642H^NK/NK NK cells displayed a distinct transcriptional profile (supplemental Figure 7A). The leukemic γδ T cells (number 8) clustered closely to the leukemic NK cells (supplemental Figure 7A). We identified significant differentially expressed genes (DEGs) in diseased N642H^NK/NK NK cells compared with all genotypes (vs controls: 888 DEGs; vs STAT5B^NK/NK: 997 DEGs; vs nondiseased N642H^NK/NK: 1038 DEGs), mainly upregulated (supplemental Figure 7B-C; supplemental Table 3). We focused on the DEGs in NK cells from diseased N642H^NK/NK mice vs controls for further analysis. To test the identified DEGs for similarities to patients with NK-cell leukemia harboring STAT5B GOF mutations, we analyzed RNA-Seq data from 64 patients with NK-cell leukemia, showing a different transcriptional profile to healthy controls (peripheral blood mononuclear cells) and other leukemias. We subdivided the patients with NK-cell leukemia according to their JAK/STAT mutations: 3 with STAT5B GOF mutations⁴⁴ (NK-cell leukemia [STAT5B GOF]), 18 with STAT3 mutations (NK-cell leukemia [STAT3 mut]), 1 with a JAK1 mutation (NK-cell leukemia [JAK1 mut]), and 44 without JAK/STAT mutations (NK-cell leukemia) (Figure 7A). Comparison of the leukemic mutant STAT5B-driven DEGs between mouse (diseased N642H^NK/NK vs control) and human (NK-cell leukemia [STAT5B GOF] vs NK-cell leukemia) identified a set of 135 common DEGs (Figure 7B; supplemental Table 4). Commonly upregulated genes included genes with oncogenic function (eg, Rras2 and Mybl1), whereas genes with tumor suppressive and proinflammatory activities were downregulated (eg, Tcf4, Dusp1, Fos, and Junb) (Figure 7C). Gene set enrichment analysis revealed 13 identical significant hallmark pathways in STAT5B GOF human and mouse leukemic NK cells (Figure 7D). All pathways were regulated in the same direction in the mouse and human STAT5B GOF comparisons. Significantly upregulated pathways were associated with cell cycle progression, whereas downregulated pathways were associated with apoptosis and inflammatory processes (Figure 7E; supplemental Figure 7D; supplemental Table 5).

Our findings show that leukemic N642H^NK/NK NK cells exhibit transcriptional patterns resembling those found in STAT5B-mutated human NK-cell leukemia, underlining the translational validity of the mouse model.

STAT5B is a prominent driver of hematopoietic diseases.¹⁸ The STAT5B^N642H mutation is primarily found in diseases arising from T/NKT cells.²⁷ Previously, a vav-STAT5B^N642H mouse model was reported to develop an aggressive CD8⁺ T-cell lymphoma.¹⁰ We now describe a mouse model (N642H^vav/+ mice; Figures 1-2) that develops slowly progressing CD4⁺, CD8⁺ T- or NKT-cell leukemia. N642H^vav/+ mice display lower pYSTAT5 levels than vav-N642H mice. The different pYSTAT5 levels could stem from a difference in transgene expression levels or might reflect the more progressive CD8⁺ T-cell disease in young vav-N642H mice. Variations in disease type and onset may result from different promoters driving transgene expression (CAG vs Vav1). N642H^vav/+ mice not only develop a CD8⁺ T-cell leukemia but also display diverse disease phenotypes, making them a closer representation of patients with STAT5B GOF mutations.⁹ Our mouse model allows for lineage- or tissue-specific transgene expression to study the impact of STAT5B^N642H in different cellular and disease contexts.

We focused on using the model to decipher STAT5B^N642H’s function in NK cells. STAT5B^N642H expression in NK cells results in hyperactive STAT5B signaling, elevated cell numbers, decreased apoptosis, increased maturation, and higher levels of lytic granzymes. The increased count of mature NK cells in 8- to 12-week-old N642H^NK/NK mice, which do not display disease symptoms, is indicative of an indolent NK-LGLL phenotype.^66,67 This finding aligns with the indolent phenotype of patients with CD4⁺ T- and NK-LGLL carrying STAT5B mutations.^12,44,46 One-third of the N642H^NK/NK mice develop an aggressive disease, suggesting that indolent cases of NK-cell malignancies can transform into aggressive phenotypes, as reported in 1 patient with NK-LGLL with a STAT5B^N642H mutation.^11,68 

Restricting STAT5B^N642H expression to NKp46⁺ cells⁶³ was crucial for the establishment of a STAT5B^N642H-driven NK-cell leukemia model, because vav-N642H^10,54 and N642H^vav/+ mice develop T-/NKT-cell but not NK-cell leukemia. NKp46 expression marks mature NK cells^64,65 and highlights them as the origin of NK-cell leukemia in N642H^NK/NK mice. In line, human indolent and aggressive NK-cell neoplasms display a mature cytotoxic phenotype.^1,69 Limited data prevent the assessment of whether STAT5B GOF mutations in patients with NK-cell leukemia are acquired in mature NK cells or at earlier developmental stages. In 1 patient with NK-LGLL, STAT5B^N642H was detected in both NK cells and a subset of NKT cells,¹¹ indicating its occurrence at a common progenitor state.

In addition to NK-cell leukemia, 1 N642H^NK/NK mouse developed γδ T-cell leukemia, consistent with NKp46 expression in subsets of γδ T cells⁷⁰ and the oncogenic potential of STAT5B^N642H in γδ T cells.⁹ Two diseased N642H^NK/NK mice showed an expansion of GFP⁺ cells lacking CD3, TCR, and NK1.1 expression, indicating an “undifferentiated” leukemia subtype. Aberrant expression of NK-cell markers has been observed in human cases of mature NK-cell malignancies,^71,72 and dedifferentiation is a common feature in several tumor types.⁷³ 

Our mouse model resembles human disease as demonstrated by comparative transcriptional analysis. The analyzed human NK-cell leukemia cohort included patients with STAT3 mutations, which occur more frequent than STAT5B mutations.^{33,36,39,41,43,44,46,68,74-83,}STAT5B GOF cases exhibited a unique transcriptional profile distinct from STAT3 mutant cases. Although both STAT3 and STAT5 act as oncogenes in hematopoietic cancers,^84-88,STAT3 mutations in NK-LGLL associate with more symptomatic cases and an expansion of cytotoxic NK cells.^{46,67,76,80,82} However, STAT3 GOF mutations alone cannot induce LGLL in mouse models,⁸⁹ unlike STAT5B^N642H, which represents a potent oncogenic driver.^9,10,54 The scarcity of STAT5B mutated cases might relate to a stronger negative feedback regulation. Excessive STAT5 activation by mutations or cytokines can induce cell death or senescence, and chronic exposure to STAT5-activating cytokines can have a negative impact on NK cells.^90-94 The initial growth/survival disadvantage observed upon STAT5B^N642H overexpression in human NK-cell lines supports this idea (supplemental Figure 3A-F) and might explain the low prevalence of aggressive leukemia cases in N642H^NK/NK mice. Further exploration is necessary to fully grasp the distinct roles of STAT3 and STAT5B mutations in human NK-cell leukemia and murine disease models.

STAT5B mutations have also been described in EBV⁺ NK-cell malignancies, such as ENKL and ANKL.^{33,36,43,61,95} Although N642H^NK/NK mice do not mimic the contribution of EBV infection, understanding the involvement of STAT5B mutations in NK-cell transformation is relevant for EBV⁺ NK-cell malignancies. Crossing our N642H^NK/NK mice with mouse models displaying conditional expression of EBV proteins^96,97 may further elucidate the interaction between EBV infection and STAT5B GOF mutations in NK-cell transformation.

Conventional therapies targeting aberrant STAT5B signaling involve JAK inhibitors. Inhibition of JAKs has drawbacks because it affects additional signaling cascades leading to unintended side effects.⁹⁸ Targeting STAT5B directly using specialized STAT inhibitors or proteolysis targeting chimeras remain challenging due to the lack of an enzymatic activity in STAT5B and its structural similarity to other STAT proteins. This underscores the importance of identifying feasible therapeutic targets downstream of mutant STAT5B. Notably, we observed a significant increase in KLRG1 on the surface of leukemic N642H^NK/NK NK cells, suggesting a potential therapeutic target. Targeting KLRG1 with monoclonal antibodies could selectively deplete malignant clones.⁹⁹ Additionally, our findings indicate immune evasion of transplanted leukemic N642H^NK/NK cells, highlighting potential therapeutic implications, particularly in the context of immunotherapies being explored in NK-cell malignancies.¹⁰⁰ 

Overall, our STAT5B^N642H-driven NK-cell leukemia mouse model closely mirrors human NK-cell leukemia representing a resource for a better understanding of NK-cell transformation, the transition from indolent to aggressive disease, and for exploring novel therapeutic interventions.

The authors thank Sabine Fajmann, Petra Kudweis, and Philipp Jodl for their experimental support; Michaela Prchal-Murphy for help and administration regarding animal experiments and ethical permits and appreciation is extended to all animal caretakers for their work; Bettina Wagner, Lill Anderson, and Tina Bernthaler for their help in the generation of the new NK cell–specific STAT5B^N642H transgenic mouse model; and Stephan Hutter (MLL Munich Leukemia Laboratory) for bioinformatics support in the analysis of primary patient samples. The authors also acknowledge the Next Generation Sequencing Facility at Vienna BioCenter Core Facilities, a member of the Vienna BioCenter, Austria, for their support. BioRender.com was used for the graphical illustration of some figures.

This work was funded in part by the Austrian Science Fund (FWF) Special Research Program SFB-F6107 (grant DOI: 10.55776/F61), the PhD program “Inflammation and Immunity” FWF W1212, Austrian Academy of Sciences funds DOC 32-B28 (grant DOI: 10.55776/DOC32), and the FWF ZK-81B (grant DOI: 10.55776/ZK81). The work was also supported by the Fellinger Cancer Research association, the City of Vienna (Stadt Wien Kultur) MA7 grant, and the University of Veterinary Medicine Vienna. K.K. is a recipient of a DOC Fellowship of the Austrian Academy of Sciences at the University of Veterinary Medicine.

Contribution: K.K., V.S., and D.G. conceived the study; T.R. and K.K. generated the mouse model; K.K., S.K., A.H., M.R., J.L., J.T., J.K., and D.G. performed the experiments; K.K., S.K., and D.G. analyzed the data; A.W.-S., C.A.B., and B.M. established methods and helped with the experiments and analysis of the data; R.M. and C.G.M. contributed to experimental design and scientific discussions; R.G., T.K., J.K., and S.K. analyzed sequencing data; G.H., W.W., and C.G.M. provided bioinformatic patient data analysis; D.G., K.K., S.K., and V.S. wrote the manuscript; D.G., and V.S. provided reagents and supervised the study; and all authors revised the manuscript.

Conflict-of-interest disclosure: G.H. and W.W. report employment by MLL Munich Leukemia Laboratory. C.G.M. received research funding from Pfizer and AbbVie; serves on the Illumina advisory board; and holds royalties in Cyrus and stocks in Amgen. The remaining authors declare no competing financial interests.

Correspondence: Dagmar Gotthardt, Department for Biological Sciences and Pathobiology, Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Veterinaerplatz 1, A-1210 Vienna, Austria; email: dagmar.gotthardt@vetmeduni.ac.at.